LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...
In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
AstraZeneca's Q3 sales rose 18% YoY to $13.6 billion Adjusted EPADS hit $1.04, exceeding expectations. U.S. investment of ...
AstraZeneca chief Pascal Soriot has said a deepening criminal probe into his company’s Chinese business is being taken “very ...
LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...
Reports Q3 revenue $13.6B, consensus $13.09B. Pascal Soriot, CEO, AstraZeneca (AZN), commenting on the results said: “Our company has ...
AstraZeneca has upgraded its annual guidance for the second time this year after sales of its cancer drugs soared in the ...
London-listed drugmaker AstraZeneca said its plan to invest 450 million pounds ($576.7 million) in Britain for vaccine ...
Jefferies analyst Peter Welford maintained a Hold rating on AstraZeneca (AZN – Research Report) today and set a price target of £114.00. The company’s shares opened today at p10,290.00. Welford ...